Dr Reddy’s Laboratories has launched Palonosetron Hydrochloride injection, a therapeutic equivalent generic version of ALOXI (palonosetron hydrochloride) injection approved by the US Food and Drug Administration (USFDA). The Aloxi brand and generic had US sales of approximately $446 million for the most recent 12 months ending in January 2018, according to IMS Health.
Dr Reddy’s Palonosetron Hydrochloride injection is available in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial, according to a release. ALoxi is a registered trademark of Helsinn Healthcare SA.